The vaginal isolate Lactobacillus paracasei LPC-S01 (DSM 26760) is suitable for oral administration
- PMID: 26441886
- PMCID: PMC4569730
- DOI: 10.3389/fmicb.2015.00952
The vaginal isolate Lactobacillus paracasei LPC-S01 (DSM 26760) is suitable for oral administration
Abstract
Bacterial vaginosis is one of the most common urogenital diseases affecting women in reproductive age. The administration of probiotics as vaginal suppository has been proposed as a strategy to cure this condition and reduce its recurrence. Nonetheless, also oral consumption of probiotics, which is a more practical route of administration, proved to be an efficient strategy. In this perspective, we studied Lactobacillus paracasei LPC-S01 (DSM 26760), a human vaginal isolate included in commercial probiotic preparations for topical use, in order to assess if this bacterium can also perform as gastrointestinal probiotic. Comparative genomics revealed the presence of several accessory genes suggesting that LPC-S01 is a niche-generalist member of its species. According to a procedure conventionally used to predict the probiotic potential, we demonstrated that the probiotic properties of strain LPC-S01, with respect to those of the well-known probiotic references L. paracasei Shirota and DG, are equal for the bile tolerance and the reduction of NF-κB activation in Caco-2 cells, or superior for the tolerance to gastric juice and the adhesion to Caco-2 epithelial cells. We then demonstrated that LPC-S01 is susceptible to antibiotics indicated by EFSA and does not produce biogenic amines. Finally, a double-blind cross-over pilot intervention trial on healthy human volunteers showed that, after a 7-days oral consumption of capsules containing about 24 billion live cells, the fecal cell concentrations of strains LPC-S01 and DG (evaluated by qPCR) were not dissimilar. Specifically, both probiotics' cell concentrations were above the detection limit for an average of 5 days from the end of the treatment, corresponding to a mean number of evacuations of 7 ± 2. Taken together, these data demonstrate that the vaginal isolate L. paracasei LPC-S01 possesses safety and functional properties that may support its use as probiotic to be administered per os for potential intestinal as well as vaginal applications.
Keywords: Caco-2 adhesion; NF-κB; gastrointestinal persistence; in vivo trial; lactobacilli; probiotic.
Figures
Similar articles
-
Effect of oral consumption of capsules containing Lactobacillus paracasei LPC-S01 on the vaginal microbiota of healthy adult women: a randomized, placebo-controlled, double-blind crossover study.FEMS Microbiol Ecol. 2020 Jun 1;96(6):fiaa084. doi: 10.1093/femsec/fiaa084. FEMS Microbiol Ecol. 2020. PMID: 32383767 Free PMC article. Clinical Trial.
-
An exploratory pilot study evaluating the supplementation of standard antibiotic therapy with probiotic lactobacilli in south African women with bacterial vaginosis.BMC Infect Dis. 2019 Sep 18;19(1):824. doi: 10.1186/s12879-019-4425-1. BMC Infect Dis. 2019. PMID: 31533663 Free PMC article. Clinical Trial.
-
Putative Adhesion Factors in Vaginal Lactobacillus gasseri DSM 14869: Functional Characterization.Appl Environ Microbiol. 2019 Sep 17;85(19):e00800-19. doi: 10.1128/AEM.00800-19. Print 2019 Oct 1. Appl Environ Microbiol. 2019. PMID: 31420338 Free PMC article.
-
Probiotics for the treatment of bacterial vaginosis.Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006289. doi: 10.1002/14651858.CD006289.pub2. Cochrane Database Syst Rev. 2009. PMID: 19821358 Review.
-
Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review.Clin Ther. 2008 Mar;30(3):453-68. doi: 10.1016/j.clinthera.2008.03.013. Clin Ther. 2008. PMID: 18405785 Review.
Cited by
-
Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health.Microb Cell Fact. 2020 Nov 7;19(1):203. doi: 10.1186/s12934-020-01464-4. Microb Cell Fact. 2020. PMID: 33160356 Free PMC article. Review.
-
Probiotic Administration Increases Amino Acid Absorption from Plant Protein: a Placebo-Controlled, Randomized, Double-Blind, Multicenter, Crossover Study.Probiotics Antimicrob Proteins. 2020 Dec;12(4):1330-1339. doi: 10.1007/s12602-020-09656-5. Probiotics Antimicrob Proteins. 2020. PMID: 32358640 Free PMC article. Clinical Trial.
-
Lactobacillus paracasei CNCM I 1572: A Promising Candidate for Management of Colonic Diverticular Disease.J Clin Med. 2022 Mar 30;11(7):1916. doi: 10.3390/jcm11071916. J Clin Med. 2022. PMID: 35407527 Free PMC article. Review.
-
Lacticaseibacillus paracasei DG enhances the lactoferrin anti-SARS-CoV-2 response in Caco-2 cells.Gut Microbes. 2021 Jan-Dec;13(1):1961970. doi: 10.1080/19490976.2021.1961970. Gut Microbes. 2021. PMID: 34365895 Free PMC article.
-
Beneficial features of pediococcus: from starter cultures and inhibitory activities to probiotic benefits.World J Microbiol Biotechnol. 2022 Nov 8;39(1):4. doi: 10.1007/s11274-022-03419-w. World J Microbiol Biotechnol. 2022. PMID: 36344843 Free PMC article. Review.
References
-
- Bastani P., Homayouni A., Ziyadi S., Tabrizian V. G. (2012). Dairy probiotic foods and bacterial vaginosis: a review on mechanism of action, in Probiotics, ed Rigobelo E. C. (Croatia: Intech publishing; ), 445–456.
LinkOut - more resources
Full Text Sources
Other Literature Sources